Red clover 

There are 21 good studies at Red clover. Here's a selection:
Abstracts with Red clover Research

2002
Red clover isoflavones significantly reduce menopausal hot flush symptoms.
Abstract Title:
Isoflavones from red clover (Promensil) significantly reduce menopausal hot flush symptoms compared with placebo.
Abstract Source:
Maturitas. 2002 Jul 25;42(3):187-93. PMID: 12161042
Abstract Author(s):
Peter H M van de Weijer, Ronald Barentsen
Abstract:
OBJECTIVES: To investigate the effectiveness and safety of a red clover isoflavone dietary supplement (Promensil, Novogen Ltd., Australia) versus placebo on the change in hot flush frequency in postmenopausal women. METHODS: In this randomized, double blind, placebo-controlled trial 30 women with more than 12 months amenorrhoea and experiencing more than five flushes per day were enrolled. All received single blind placebo tablets for 4 weeks and were subsequently randomized to either placebo or 80 mg isoflavones for a further 12 weeks. Efficacy was measured by the decrease in number of hot flushes per day and changes in Greene Climacteric Scale Score. RESULTS: During the first 4 weeks of placebo the frequency of hot flushes decreased by 16%. During the subsequent double blind phase, a further, statistically significant decrease of 44% was seen in isoflavones group (P<0.01), whereas no further reduction occurred within the placebo group. The Greene score decreased in the active group by 13% and remained unchanged in the placebo group. CONCLUSION: In this study, treatment with 80 mg isoflavones (Promensil) per day resulted in a significant reduction in hot flushes from baseline. At the end of the study there was a significant decrease in hot flushes of 44% between the active and placebo group, demonstrating the effectiveness of Promensil in the management of hot flushes.
Article Published Date : Jul 25, 2002
Study Type : Human Study
Additional Links
Substances : Red Clover : CK(40) : AC(11)
Diseases : Hot Flash : CK(253) : AC(28)

2004
Isoflavones attenuate bone loss and have a potentially protective effect on the lumbar spine in women.
Abstract Title:
The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial.
Abstract Source:
Am J Clin Nutr. 2004 Feb;79(2):326-33. PMID: 14749241
Abstract Author(s):
Charlotte Atkinson, Juliet E Compston, Nicholas E Day, Mitch Dowsett, Sheila A Bingham
Abstract:
BACKGROUND: Isoflavone phytoestrogen therapy has been proposed as a natural alternative to hormone replacement therapy (HRT). HRT has a beneficial effect on bone, but few trials in humans have investigated the effects of isoflavones on bone. OBJECTIVE: The objective of the study was to determine the effect on bone density of a red clover-derived isoflavone supplement that provided a daily dose of 26 mg biochanin A, 16 mg formononetin, 1 mg genistein, and 0.5 mg daidzein for 1 y. Effects on biochemical markers of bone turnover and body composition were also studied. DESIGN: Women aged 49-65 y (n = 205) were enrolled in a double-blind, randomized, placebo-controlled trial; 177 completed the trial. Bone density, body composition, bone turnover markers, and diet were measured at baseline and after 12 mo. RESULTS: Loss of lumbar spine bone mineral content and bone mineral density was significantly (P = 0.04 and P = 0.03, respectively) lower in the women taking the isoflavone supplement than in those taking the placebo. There were no significant treatment effects on hip bone mineral content or bone mineral density, markers of bone resorption, or body composition, but bone formation markers were significantly increased (P = 0.04 and P = 0.01 for bone-specific alkaline phosphatase and N-propeptide of collagen type I, respectively) in the intervention group compared with placebo in postmenopausal women. Interactions between treatment group and menopausal status with respect to changes in other outcomes were not significant. CONCLUSION: These data suggest that, through attenuation of bone loss, isoflavones have a potentially protective effect on the lumbar spine in women.
Article Published Date : Feb 01, 2004
Study Type : Human Study
Additional Links
Substances : Isoflavones : CK(635) : AC(132), Red Clover : CK(40) : AC(11)
Diseases : Osteoporosis : CK(1302) : AC(257)

2008
Red clover demonstrates aromatase inhibition activity, which may reduce the risk of estrogen receptor positive breast cancer.
Abstract Title:
The red clover (Trifolium pratense) isoflavone biochanin A inhibits aromatase activity and expression.
Abstract Source:
Br J Nutr. 2008 Feb;99(2):303-10. Epub 2007 Aug 29. PMID: 17761019
Abstract Author(s):
Yun Wang, Wai Man Gho, Franky L Chan, Shiuan Chen, Lai K Leung
Abstract:
Biochanin A is an isoflavone isolated from red clover (Trifolium pratense), and is a commercially available nutraceutical for women suffering from postmenopausal symptoms. Isoflavones resemble the structure of oestrogen, and display agonistic and antagonistic interactions with the oestrogen receptor. Overexposure of oestrogen is a major contributing factor in the development of breast cancer, and cytochrome P450 (CYP) 19 enzyme, or aromatase, catalyses the reaction converting androgen to oestrogen. In the present study the effect of biochanin A on the gene regulation and enzyme activity of aromatase was investigated. By assaying MCF-7 cells stably transfected with CYP19, biochanin A inhibited aromatase activity and hampered cell growth attributing to the enzyme activity. In addition, 25 microm-biochanin A significantly reduced CYP19 mRNA abundance in the oestrogen receptor-negative breast cancer cells SK-BR-3. The transcriptional control of the CYP19 gene is exon-specific, and promoter regions I.3 and II have been shown to be responsible for CYP19 expression in SK-BR-3 cells. Luciferase reporter gene assays also revealed that biochanin A could repress the transcriptional control dictated by the promoter regulation. Interestingly, genistein did not inhibit aromatase but it might down regulate promoter I.3 and II transactivation. Since genistein is a major metabolite of biochanin A, it might contribute to biochanin A's suppressive effect on CYP19 expression. The present study illustrated that biochanin A inhibited CYP19 activity and gene expression.
Article Published Date : Feb 01, 2008
Study Type : In Vitro Study
Additional Links
Substances : Biochanin A : CK(9) : AC(8), Red Clover : CK(40) : AC(11)
Diseases : Breast Cancer : CK(3592) : AC(1064)
Pharmacological Actions : Aromatase Inhibitors : CK(37) : AC(27)

You will find much more in the following links on the Red Clover:
________________________________________________________

https://www.ncbi.nlm.nih.gov/pmc/?term=red+clover
https://www.greenmedinfo.com/substance/red-clover

PubMed
PubMed comprises more than 28 million citations for biomedical literature from MEDLINE, life science journals, and online books.
In PubMed
There are 8016 on Red Clover. 

13 Diseases Researched for Red Clover
Menopausal Syndrome313
Hot Flash110
Osteoporosis110
Neurodegenerative Diseases12
Obesity12
Brain Cancer11
Breast Cancer11
Cardiovascular Diseases11
Glioblastoma11
Lipopolysaccharide-Induced Toxicity11
Metabolic Syndrome X11
Prostate Cancer11
Prostatic Hyperplasia: Benign11

8 Pharmacological Actions Researched for Red Clover
Apoptotic22
Neuroprotective Agents12
Prophylactic Agents12
Anti-Inflammatory Agents11
Aromatase Inhibitors11
Interleukin-10 upregulation11
Interleukin-6 Downregulation11
Tumor Necrosis Factor (TNF) Alpha Inhibitor